MedImmune Gets Closer To Abbott With U.S. Bioscience Merger
Executive Summary
MedImmune's acquisition of U.S. Bioscience will likely lead to a tighter relationship with Abbott. Abbott already co-markets MedImmune's Synagis (palivizumab) and is in the process of acquiring Alza, which co-promotes U.S. Bioscience's top product Ethyol (amifostine) in the U.S.